CytomX Therapeutics Inc (NASDAQ:CTMX) Director Frederick W. Gluck sold 5,000 shares of CytomX Therapeutics stock in a transaction on Tuesday, December 26th. The stock was sold at an average price of $22.29, for a total value of $111,450.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
CytomX Therapeutics Inc (CTMX) opened at $25.17 on Friday. CytomX Therapeutics Inc has a one year low of $11.06 and a one year high of $25.60. The firm has a market cap of $966.75 and a PE ratio of -16.03.
Hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc raised its stake in CytomX Therapeutics by 28.6% in the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 1,434 shares during the last quarter. Macquarie Group Ltd. acquired a new position in CytomX Therapeutics in the 3rd quarter valued at about $107,000. Cubist Systematic Strategies LLC acquired a new position in CytomX Therapeutics in the 2nd quarter valued at about $174,000. Goldman Sachs Group Inc. acquired a new position in CytomX Therapeutics in the 1st quarter valued at about $190,000. Finally, Voya Investment Management LLC acquired a new position in CytomX Therapeutics in the 2nd quarter valued at about $203,000. 63.13% of the stock is owned by hedge funds and other institutional investors.
CTMX has been the subject of several research reports. Bank of America lifted their price target on CytomX Therapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Nomura lifted their price target on CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Wedbush set a $37.00 price target on CytomX Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research note on Monday, October 16th. Finally, Citigroup initiated coverage on CytomX Therapeutics in a research note on Friday, January 5th. They set a “buy” rating and a $40.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. CytomX Therapeutics currently has an average rating of “Buy” and an average target price of $32.78.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/14/frederick-w-gluck-sells-5000-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.